Şunu aradınız:: antikoagulandile (Estonca - İngilizce)

pradaxa-ravilt parenteraalsele antikoagulandile
pradaxa treatment to parenteral anticoagulant

pradaxa- ravilt parenteraalsele antikoagulandile üleviimine:
switching from pradaxa treatment to parenteral anticoagulant:

17 pradaxa- ravilt parenteraalsele antikoagulandile üleviimine:
17 switching from parenteral anticoagulants treatment to pradaxa:

Üleminekul mistahes alternatiivsele antikoagulandile tuleb tagada pidev piisav antikoagulatsioon.
continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant.

Üleminekul alternatiivsele antikoagulandile tuleb alati tagada piisava hüübimisvastase toime jätkumine.
continuous adequate anticoagulation should be ensured during any transition to an alternate anticoagulant.

ravimit ei tohi kasutada patsiendid, kes võtavad muud antikoagulanti, välja arvatud erijuhtudel, näiteks teisele antikoagulandile üleminekul.
it must not be used in patients taking any other anticoagulant medicine, except in specific situations such as when the anticoagulant medication is being switched.

betaiini manustamine raseduse ajal lisaks püridoksiinile, folaadile, antikoagulandile ja dieedile vereplasma homotsüsteiinitaseme hoolika jälgimisega on ema ja loote tervisele kasulik.
during pregnancy, administering betaine in addition to pyridoxine, folate, anticoagulant and diet under close monitoring of plasma homosysteine would be compatible with good maternal and foetal outcomes.

veevaba betaiini manustamine raseduse ajal lisaks püridoksiinile, folaadile, antikoagulandile ja dieedile vereplasma homotsüsteiinitaseme hoolika jälgimisega on ema ja loote tervisele kasulik.
during pregnancy, administering betaine anhydrous in addition to pyridoxine, folate, anticoagulant and diet under close monitoring of plasma homocysteine would be compatible with good maternal and foetal outcomes.

soovitatakse mööda lasta 12 tundi pärast viimast annust, enne kui minnakse üle dabigatraaneteksilaadilt parenteraalsele antikoagulandile (vt lõik 4.5).
it is recommended to wait 12 hours after the last dose before switching from dabigatran etexilate to a parenteral anticoagulant (see section 4.5).

xigrise toimeaine on alfa- drotrekogiin (aktiveeritud), mis on väga sarnane organismis leiduvale looduslikule antikoagulandile, aktiveeritud proteiin c- le.
the active ingredient of xigris is drotrecogin alfa (activated), which is very similar to a natural anticoagulant found in the body called activated protein c.

enne pradaxa’lt parenteraalsele antikoagulandile üleminekut on soovitatav vahele jätta 24-tunnine intervall pärast pradaxa viimast annust (vt lõik 4.5).
it is recommended to wait 24 hours after the last dose before switching from pradaxa to a parenteral anticoagulant (see section 4.5).

xigrise toimeaine aktiveeritud alfadrotrekogiin on väga sarnane organismis sisalduvale looduslikule antikoagulandile aktiveeritud proteiinile c. alfadrotrekogiini valmistatakse rekombinant-dna-tehnika abil: seda toodab rakk, millele on lisatud alfadrotrekogiini teket võimaldav geen (dna).
the active substance in xigris, drotrecogin alfa (activated), is very similar to a natural anticoagulant found in the body called activated protein c. drotrecogin alfa is produced by a method known as ‘recombinant dna technology’: it is made by a cell that has received a gene (dna), which makes it able to produce drotrecogin alfa.